The reactions to and antigenicity of two human-rhesus rotavirus (RRV) reassortants (human rotavirus strain D x RRV and human rotavirus strain DS1 x RRV) with the VP7 neutralization specificity of a serotype 1 or serotype 2 rotavirus were evaluated in a placebo-controlled double-blind trial in 116 1-to 5-month-old infants in Caracas, Venezuela. The children were randomly divided into five groups to receive orally the following inocula: (i) 104 PFU of D x RRV reassortant; (ii) i04 PFU of DS1 x RRV reassortant; (iii) 1 PFU of RRV; (iv) 
The importance of rotavirus as a cause of severe diarrhea in children of developing countries has been highlighted in cross-sectional and longitudinal studies (11) . An effective rotavirus vaccine administered to infants under 6 months of age in the developing countries may decrease the number of cases of diarrhea by more than 50 million episodes and prevent up to 800,000 deaths per year (3) . There is thus an urgent need for trials of the different vaccine candidates to accelerate their practical application.
Current strategies for the development of rotavirus vaccines are based on the Jennerian approach, which takes advantage of the antigenic relatedness of human and animal rotaviruses and the diminished virulence of animal rotavirus strains for humans (13) . Under this concept, the bovine strain NCDV (RIT 4237; Smith-Kline, Rixensart, Belgium) was tested in several studies in humans. For instance, when administered orally as a single dose to 8-to 11-month-old children in Finland, this vaccine did not cause side effects and had efficacies of 88% against clinically significant rotavirus diarrheal episodes lasting more than 24 h and 50% against all rotavirus diarrheas (22) . In a subsequent study, 6-to 12-month-old infants were given two doses of this vaccine, which resulted in 82% protection against clinically significant rotavirus diarrhea and 58% protection against all rotavirus diarrheas (21) . More recent studies have shown that its antigenicity is rather low in younger infants and in newborns. This may have been the cause for the vaccine failure in studies in Rwanda (2) and Gambia (8) .
A simian strain, rhesus rotavirus (RRV) MMU-18006, has also undergone extensive clinical evaluation as a vaccine candidate (14) . This virus is antigenically related to human rotavirus serotype 3. It is more antigenic but induces more reactions than the RIT 4237 vaccine (23) . More than 500 infants have received this vaccine (13, 19) . Reactions occur * Corresponding author.
in a range of 0 to 30% of infants receiving a 104 PFU dose and consist of a low-grade transient fever. Preliminary observations from phase 2 studies in Maryland (Baltimore), Venezuela, and Finland revealed that the 104 PFU dose of RRV vaccine induced protective immunity; however, the vaccine failed to induce resistance in studies in New York (Rochester) and Arizona (13) . This difference appears to be due at least in part to the circulating wild-type serotype prevalent in the community. Thus, in the Venezuelan study, where a high degree of protection against severe diarrhea was observed, a majority of the rotaviruses isolated were serotype 3 strains, that is, the same serotype as the vaccine (4). In contrast, almost all of the rotaviruses detected in vaccinees and controls in Rochester and Arizona belonged to serotypes other than type 3, indicating a lack of heterotypic immunity (13) .
Since homotypic immunity appears to be important in protection against rotavirus disease, a modified Jennerian approach has been adopted in which RRV vaccine is used as a donor of attenuating genes in reassortant viruses bearing the major neutralization protein (VP7) of a human rotavirus belonging to serotype 1, 2, or 4. In this way, human-RRV reassortants possessing a single gene from the human virus (that which encodes VP7) and the remaining 10 genes from the animal virus have been prepared for serotypes 1, 2, and 4 (16, 17) . In this study, we evaluated the antigenicity of and reactions to two such reassortants (serotypes 1 and 2) and compared these properties with those of RRV. 320  13  86d  320  10  2  205  320  14  26e  20  17  114  80  29  280e  320  26  3  123  160  8  24e  20  14  84  80  13  166  160  19  4  80e  80  9  22e  20  12  68e  80  13  166  320  19  5  33  20  9  27  20  9  101 Table 2 presents the relationship between age and the plaque reduction neutralization (PRN) antibody titers against the different rotavirus serotypes prior to vaccination. One-month-old infants had significantly higher levels of preexisting antibodies against Wa (serotype 1) than against DS1 (serotype 2), P (serotype 3), and RRV (serotype 3). These high levels of Wa antibody decreased quickly such that the levels detected in infants of 3, 4, and 5 months old were significantly lower. Preexisting antibodies to DS1 were lowest and also showed a significant decline in infants 2, 3, and 4 months old in comparison with the 1-month-old group. Likewise, antibodies to the P strain were highest in the 1-month-old infants and dropped progressively through month 4 such that they were significantly lower in the 4-month-old infants than in the 1-month-old group. Neutralizing antibody levels against RRV were significantly higher in infants 2 and 5 months of age than in the 1-month-old group.
Neutralization antibody seroresponses to the vaccines. Children receiving placebo were only tested against the human serotype 3 strain P. Only 1 of 19 controls tested developed a fourfold or greater antibody response to this virus ( Table 3) . The geometric mean titer (GMT) for the placebo group against the P strain decreased from 1:125 to 1:89 during the 4-week postvaccination period (Table 4) .
Infants receiving the D x RRV reassortant vaccine were tested for seroresponses by PRN to the homotypic serotype 1 antigen Wa (with which the reassortant shares its VP7 antigen), as well as to heterotypic strains serotype 2 DS1, serotype 3 P. and serotype 3 RRV (with which it shares VP4). As seen in Table 3 , 39% of the children developed a homotypic response to the Wa virus; heterotypic responses against DS1 and P were observed in 25% of the infants.
Infants who received the DS1 x RRV reassortant were examined for seroresponses to the homotypic strain DS1 (with which this reassortant shares the VP7 antigen) and RRV (with which it shares VP4). Fourfold or greater antibody rises against DS1 and RRV strains were detected in 52 and 65% of the vaccines, respectively ( Table 3) .
The sera from infants receiving RRV were tested against the homologous virus and the human strain P (with which RRV shares VP7 but not VP4) ( Table 3 ). The frequency of seroresponse to the RRV (60%) tended to be greater than that to the P strain (32%). Children who were vaccinated with a combined D x RRV and RRV vaccine were tested against Wa, DS1, P, and RRV antigen. As shown in Table 3 , over one-half of the children developed a seroresponse to the Wa and RRV antigens (57 and 63%, respectively), whereas 47% responded to the P virus and 35% to DS1.
The geometric mean titers of neutralizing antibody in each vaccine group against each of the antigens tested is shown in Table 4 .
Relationships between age, preexisting antibody titers, and seroresponses. Table 5 summarizes the seroresponses by neutralization for each vaccine group on the basis of age at time of vaccine administration. The frequency of homotypic responses to the Wa virus induced by the D x RRV (alone) was significantly greater in the 3-to 5-month-old group than in the 1-to 2-month-old group. A similar tendency was observed with the D x RRV plus RRV combination. No significant differences in the responses to the DS1 x RRV vaccine were observed between these age groups. However, the seroresponses to P were significantly higher in 3-to 5-month-old infants receiving D x RRV along with RRV than in the 1-to 2-month-old group. The relationship be- tween the level of preexisting neutralizing antibody titers and the development of a seroresponse was also examined. Table 6 shows that seroresponses were characteristically more common in infants with lower levels of preexisting antibody. Overall, homotypic responses were detected in 77% of the sera tested in which preexisting antibody levels were lower than 1:320. In contrast, when preexisting antibody levels were equal to or higher than 1:320, responses were only observed in 27% of the sera (P < 0.01).
Serological responses measured by IgA ELISA. Since the ability to detect seroresponses may have been masked by preexisting maternal antibody, we examined paired sera by an IgA ELISA. IgA antibody is not transferred from the mother to the infant. IgA antibody rises were demonstrated significantly more often in infants from each of the vaccine groups than in the controls (P < 0.01); 57 to 88% of the children tested exhibited responses (Table 3) .
Vaccine shedding. Most of the stools obtained during the week postvaccination were negative when tested directly for rotavirus by ELISA. Tissue culture isolation of rotavirus from stools obtained 3 and 5 days after vaccination revealed that 53 to 86% of the vaccinated infants shed virus in the stool ( Table 7) . Serotyping of a few of the cultures from each vaccine group confirmed that the rotavirus shed in the stools was the same as the vaccine administered.
DISCUSSION
In the present study, we tested two human-RRV reassortant vaccines, each of which contained 10 genes from RRV and a single gene which encodes the neutralization protein (VP7) from human rotavirus serotype 1 (D x RRV) or 2 (DS1 x RRV) (16) . In addition, the RRV vaccine (serotype 3) or a combination of D x RRV and RRV was evaluated. The study population consisted of 1-to 5-month-old infants from areas of low socioeconomic conditions in Caracas. Although individual vaccines tended to induce low-grade fevers and loose stools more frequently than the controls, serious reactions were not observed. However, it is clear that the vaccines as a group induced low-grade fever in 18% and diarrhea in 11% of the vaccinees. There were no cases of severe diarrhea; 10 vaccinees developed mild diarrhea for 1 (6 infants) or 2 (4 infants) days, none of them requiring any treatment. Development of reactions did not appear to correlate with either the age of the children or the level of preexisting antibody. The combined postvaccination symptoms observed corresponded to a score of 0 to 4 by the diarrheal severity score system used by us in previous studies (4) . In those studies, the score for naturally occurring rotavirus diarrheal illnesses ranged from 5 to 12 points (median, 8). We have no explanation for the higher occurrence of coughing observed in the vaccine recipients than in the control infants. Such a finding, however, has not been made in more recent, unpublished studies. The reactions observed with the reassortants were comparable with those found with the same dose of RRV, indicating that the replacement of the RRV gene encoding the VP7 protein with the corresponding gene from human strains D and DS1 did not appear to increase its virulence.
Since growing evidence indicates that VP4 (the other outer capsid protein of rotavirus) is also capable of inducing neutralizing activity (9, 18) we tested the paired sera (preand postvaccination) of the vaccinees against human rotavirus strains Wa, DS1, and P which have a VP4 antigenically different from that of RRV or the RRV reassortants used. (6) . The serotype 2 DS1 strain used in the neutralization assays was the same as the VP7 gene donor used in the DS1 x RRV reassortant, and the VP7 of serotype 3 strain P is indistinguishable from that of RRV (6) . Testing the sera against these human strains not only permits a prediction of their value as vaccines against human rotaviruses but also allows, at least partially, the dissection of neutralization seroresponses into their two components (VP4 and VP7). Administration of D x RRV reassortant induced seroresponses to the VP7 homotypic Wa strain in 9 of 23 infants. It is interesting that these responses were observed only in the older (3-to 5-month-old) infants studied. It is likely that the higher preexisting antibody titers against Wa in the youngest infants (most likely maternally derived) may have played a role in their lack of detectable responses. The same phenomenon was observed in infants who received the vaccine combination; their responses to Wa appeared to have been modulated by the high level of preexisting antibody.
In contrast, preexisting antibody titers to the DS1 strain were rather low (perhaps a result of a lower prevalence of this serotype in these communities prior to the time of the study). Overall, 52% of the infants receiving DS1 x RRV RRV developed seroresponses to the P strain. The low preexisting antibody titers to DS1 and the fact that only 2 of the 4 infants responding heterotypically to P had preexisting antibodies (at a 1:40 level) suggest that these infants had not been previously infected with these serotypes. Although maternally derived antibody cannot be distinguished from antibodies acquired by active infection, the young age of the infants studied here and the low levels of anti-rotavirus IgA detected in most of them would suggest that the homotypic as well as the heterotypic responses observed were the products of a primary infection. It is possible that the low frequency of neutralization responses detected in some cases may be due to difficulties in detecting small titer changes over a large background of preexisting antibody.
The heterotypic responses observed in this study are in contrast with responses observed after hyperimmunization of animals, in which homotypic antibodies are predominantly induced. Similarly, the significant neutralization responses to VP4 following oral immunization observed in our study contrast markedly with the responses observed in animals following parenteral inoculation in which VP7 neutralizing antibody responses predominate (10) . This indicates that VP4 plays a role in the development of neutralizing responses after rotavirus infection in children.
Shedding of vaccine virus was observed in over 50% of the infants. It appears that this represents intestinal virus replication rather than passive passage of the vaccine strain since in most cases shedding could be detected at 5 days after vaccination. Also, because of the relatively small dose of vaccine used the recovery of passaged (nonreplicated) virus would have been unlikely. In some infants (especially the younger ones), viral shedding was detected in the absence of antibody rises. When viral shedding and seroresponses are combined, the frequency of takes for each virus is quite remarkable: 20 of 23 D x RRV recipients, 24 of 24 DS1 x RRV recipients, 18 of 21 RRV recipients, and 20 of 22 D x RRV plus RRV recipients.
Although information available from protection studies with RRV vaccine is still scanty, it appears that this vaccine induces only serotype-specific immunity. Thus, studies in Venezuela indicate that RRV vaccine was highly protective at a time when serotype 3 strains were prevalent (4); on the other hand, studies in Rochester and Arizona indicate that RRV vaccine does not protect against serotype 1 diarrheal illness (13) . Likewise, recent observations of natural rotavirus infection and reinfections by Chiba et al. (1) in Japan demonstrated that homotypic antibody titers of 1:128 or greater (as measured by tube neutralization assays) were required to protect children at risk during an epidemic of serotype 3 rotavirus.
The induction of homotypic responses with the strains tested in this study, as well as the observation of heterotypic responses in some infants, offers promise towards their use as vaccines. The suggestion that a synergistic effect is induced by the simultaneous administration of serotypes 1 and 3 supports the possibility that polyvalent vaccines might afford cross-reactive immunity.
Presently, four human rotavirus serotypes are considered to be epidemiologically important (5, 7, 24) . Therefore, the development of a quadrivalent rotavirus vaccine formulation which includes all four serotypes may represent an important step forward in the prevention of rotavirus diarrhea. Further studies (including efficacy testing) with the individual reassortants reported here and a serotype 4 RRV reassortant already developed (17) , as well as studies with a quadrivalent vaccine, are currently in progress to accelerate achievement of this goal.
